Avicanna Announces Organizational Change in Avicanna LATAM S.A.S
30 déc. 2022 07h30 HE
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement
21 déc. 2022 17h00 HE
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO Phyto™ CBG Transdermal Gel Topical Product
14 déc. 2022 07h33 HE
|
Avicanna Inc.
TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market
29 nov. 2022 07h30 HE
|
Avicanna Inc.
Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC...
Avicanna Reports Q3 2022 Financial Statement
14 nov. 2022 07h30 HE
|
Avicanna Inc.
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY...
Avicanna Announces Closing of Non-Brokered Private Placement
11 nov. 2022 07h30 HE
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Announces Extension of Term Loan
31 oct. 2022 17h00 HE
|
Avicanna Inc.
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
20 oct. 2022 07h30 HE
|
Avicanna Inc.
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
18 oct. 2022 07h30 HE
|
Avicanna Inc.
The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain...
Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto
15 sept. 2022 09h09 HE
|
Avicanna Inc.
Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and...